SCHEMBL20639017

SCHEMBL20639017

CC(C)(C)c1cc(Cl)c(C(=O)O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GABRP O00591 2/20 0.40
GABRD O14764 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB1 P18505 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40
GABRA2 P47869 2/20 0.40
GABRB2 P47870 2/20 0.40
GABRA4 P48169 2/20 0.40
GABRE P78334 2/20 0.40
GABRA6 Q16445 2/20 0.40
GABRG1 Q8N1C3 2/20 0.40
GABRG3 Q99928 2/20 0.40
GABRQ Q9UN88 2/20 0.40
NNMT P40261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31697155 1.00 TSHR (0.40) TSHRCASP1SMN1; SMN2GABRPGABRD
SCHEMBL29754010 0.84 ASPH (0.46) TSHRCASP1SMN1; SMN2SORT1KDM4E
SCHEMBL14921073 0.84 ASPH (0.46) TSHRCASP1SMN1; SMN2SORT1KDM4E
SCHEMBL17816222 0.81 MAPT (0.45) TSHRSMN1; SMN2NNMTKDM4ELMNA
SCHEMBL19711942 0.81 ASPH (0.40) TSHRCASP1SMN1; SMN2GABRPGABRD
SCHEMBL17816223 0.80 POLB (0.54) TSHRNNMTALDH1A1
SCHEMBL17648758 0.78 BAZ2B (0.50) KDM4ECA12CA1CA2CA9
SCHEMBL30614604 0.76 CSNK2A1 (0.44) CASP1GABRPGABRDGABRA1GABRB1
SCHEMBL1105936 0.76 GABRP (0.47) TSHRCASP1SMN1; SMN2GABRPGABRD
SCHEMBL25340523 0.75 KDM4E (0.58) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441703-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-10-14 US disclosed
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 US disclosed
US-20230062053-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2023-03-02 US disclosed
US-20230062053-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2023-03-02 US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 US disclosed
WO-2020146682-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-07-16 WO disclosed
WO-2020146682-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-07-16 WO disclosed
EP-3651752-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2020-05-20 EP disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 US disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 US disclosed
CN-111065383-A Carboxamides useful as sodium channel modulators 沃泰克斯药物股份有限公司 2020-04-24 CN disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 WO disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 WO disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 US disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-10647661-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-12441703-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-20230062053-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TSHR 3163/4885CASP1 2086/4885SMN1; SMN2 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.